Transferability of a European-derived Alzheimer's Disease Genetic Risk Score across Multi-Ancestry Populations.

Aude Nicolas[1], Benjamin Grenier-Boley[1], Richard Sherva[2,3], Yoontae Kim[4], Masataka Kikuchi[5], Itziar de Rojas[6,7], Carolina Dalmasso[8,9], Xiaopu Zhou[10,11,12], Yann Le Guen[13,14], Carlos E Arboleda-Bustos[15], Maria Aparecida Camargos Bicalho[16,17,18], Maëlenn Guerchet[19], Sven van der Lee[20,21], Monica Goss[22], Atahualpa Castillo[23], Céline Bellenguez[1], Fahri Küçükali[24,25], Claudia Satizabal Barrera[22,26,27], Bernard Fongang[22,28,29], Qiong yang[26,27], Oliver Peters[30,31], Anja Schneider[32,33], Martin Dichgans[34,35,36], Dan Rujescu[37], Norbert Scherbaum[38], Jürgen Deckert[39], Steffi Riedel-Heller[40], Lucrezia Hausner[41], Laura Molina Porcel[42,43], Emrah Düzel[44,45], Timo Grimmer[46], Jens Wiltfang[47,48,49], Stefanie Heilmann-Heimbach[50], Susanne Moebus[51], Thomas Tegos[52], Nikolaos Scarmeas[53,54], Oriol Dols-Icardo[55,7], Fermin Moreno[56,7,57], Jordi Pérez-Tur[58,7], María J. Bullido[59,7,60,61], Pau Pastor[62,63], Raquel Sánchez-Valle[64], Victoria Álvarez[65,66], Han Cao[10], Nancy Y. Ip[10,11,12], Amy K. Y. Fu[10,11,12], Fanny C. F. Ip[11,12], Natividad Olivar[67], Carolina Muchnik[67], Carolina Cuesta[68], Lorenzo Campanelli[69], Patricia Solis[70], Daniel Gustavo Politis[68], Silvia Kochen[70], Luis Ignacio Brusco[67], Mercè Boada[71,7], Pablo García-González[71], Raquel Puerta[71], Pablo Mir[72,7], Luis M Real[73,74,7], Gerard Piñol-Ripoll[75,76], Jose María García-Alberca[77,7], Jose Luís Royo[78], Eloy Rodriguez-Rodriguez[79,7], Hilkka Soininen[80], Sami Heikkinen[81], Alexandre de Mendonça[82], Shima Mehrabian[83], Latchezar Traykov[84], Jakub Hort[85,86], Martin Vyhnalek[85,86], Katrine Laura Rasmussen[87,88], Jesper Qvist Thomassen[87], Yolande A.L. Pijnenburg[20], Henne Holstege[20,89], John van Swieten[90], Inez Ramakers[91], Frans Verhey[91], Aad van der Lugt[92], Philip Scheltens[20], Jenny Ortega-Rojas[15], Ana Gabriela Concha Mera[15], Maria F. Mahecha[15], Rodrogo Pardo[15], Gonzalo Arboleda[15], Caroline Graff[93], Goran Papenberg[94], Vilmantas Giedraitis[95], Anne Boland[96], Jean-François Deleuze[96], Luiz Armando de Marco[97,17], Edgar Nunes de Moraes[16,18], Bernardo de Mattos Viana[98,17,99], Marco Túlio Gualberto Cintra[16,18], Anthony Grsiwold[100], Tatiana Forund[101], Carlos Cruchaga[102,103], Jonathan Haines[104], Lindsay Farrer[105,106,107,108,109], Anita DeStefano[110], Ellen Wijsman[111,112,113], Richard Mayeux[114,115], Margaret Pericak-Vance[100,116], Brian Kunkle[100], Alison Goate[117], Gerard D. Schellenberg[118], Badri Vardarajan[114,115,119], Li-San Wang[118], Yuk Yee Leung[118], Clifton Dalgard[120], Gael Nicolas[121], David Wallon[121], Carole Dufouil[122,123], Florence Pasquier[124], Olivier Hanon[125], Stéphanie Debette[126,127], Edna Grünblatt[128,129,130], Julius Popp[131,132,133], Bárbara Angel[134,135], Sergio Golger[136,137], Maria Victoria Chacon[136], Rafael Aranguiz[136,138], Paulina Orellana[139,140], Andrea Slachevsky[139,141], Christian Gonzalez-Billault[139], Cecilia Albala[134,142], Patricio Fuentes[143,144], Tenielle Porter[145,146,147], Simon M Laws[145,146,147], Perminder Sachdev[148], Karen Mather[148], Richard L. Hauger[149,150], Victoria Merritt[151,152,153], Matthew Panizzon[152,154,153], Rui Zhang[2], Michael Gaziano[155,156], Roberta Ghidoni[157], Daniela Galimberti[158,159], Beatrice Arosio[160], Patrizia Mecocci[161,162], Vincenzo Solfrizzi[163], Lucilla Parnetti[164], Alessio Squassina[165], Lucio Tremolizzo[166], Barbara Borroni[167,168], Benedetta Nacmias[169,170], Paolo Caffarra[171], Davide Seripa[172], Innocenzo Rainero[173], Antonio Daniele[174,175], Fabrizio Piras[176], Akinori Miyashita[177], Norikazu Hara[177], Kouichi Ozaki[178], Shumpei Niida[178], Julie Williams[179,23], Carlo Masullo[180], Philippe Amouyel[180], Pierre-Marie Preux[19], Pascal Mbelesso[19,181], Bébène Bandzouzi[182], Andy Saykin[183,101], Frank Jessen[184,32,185], Patrick Kehoe[186], Cornelia Van Duijn[187,188], Jungsoo Gim[4], Nesrine Ben Salem[189], Ruth Frikke-Schmidt[87,88], Lofti Cherni[189,190], Michael D. Greicius[13], Magda Tsolaki[52,190], Pascual Sánchez-Juan[191,7], Marco Aurélio Romano Silva[98,17], Kristel Sleegers[24,25], Martin Ingelsson[192,193,194], Jean-François Dartigues[195], Sudha Seshadri[22,26,27], Giacomina Rossi[196], Laura Morelli[69], Mikko Hiltunen[81], Rebecca Sims[23], Wiesje van der Flier[20], Ole Andreassen[197,198], Humberto Arboleda[15], Valentina Escott-Price[199,179], Agustín Ruiz[200,7], Kun Ho Lee[4], Takeshi Ikeuchi[177], Alfredo Ramirez[8,201,202,32], Mark Logue[203,204,205,206], Jean-Charles Lambert[1]

Correspondence
Jean-Charles.lambert@pasteur-lille.fr

[1]Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Lille, France
[2]National Center for PTSD, Behavioral Sciences Division, VA Boston Healthcare System, Boston, MA, USA
[3]Biomedical genetics/Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA, USA
[4]BK FOUR Department of Integrative Biological Sciences, Chosun University, Gwangju, Republic of Korea
[5]University of Tokyo, Graduate School of Frontier Science, Japan
[6]Research Center and Memory Clinic, ACE Alzheimer Center Barcelona. Universitat Internacional de Catalunya, Spain
[7]CIBERNED, Network Center for Biomedical Research in Neurodegenerative Diseases, National Institute of Health Carlos III, Madrid, Spain
[8]Division of Neurogenetics and Molecular Psychiatry, Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
[9]Estudios en Neurociencias y Sistemas Complejos (ENyS) CONICET-HEC-UNAJ, Argentina
[10]Division of Life Science, State Key Laboratory of Molecular Neuroscience, Molecular Neuroscience Center, The Hong Kong University of Science and Technology, Clear Water Bay, Kowloon, Hong Kong, China
[11]Hong Kong Center for Neurodegenerative Diseases, Hong Kong Science Park, Hong Kong, China
[12]Guangdong Provincial Key Laboratory of Brain Science, Disease and Drug Development, HKUST, China Shenzhen Research Institute, Shenzhen–Hong Kong Institute of Brain Science, Shenzhen, Guangdong 518057 China
[13]Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, CA, USA
[14]Institut du Cerveau - Paris Brain Institute - ICM, Paris, France
[15]Neuroscience and Cell Death Research Groups, Medical School and Genetic Institute, Universidad Nacional de Colombia, Bogota, Colombia
[16]Department of Clinical Medicine, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Geraes, Brazil
[17]National Institute of Science and Technology (INCT) Neurotec R, Federal University of Minas Geraes, Belo Horizonte, Minas Geraes, Brazil
[18]Geriatrics Service of the University Hospital, Federal University of Minas Gerais, Belo Horizonte, Minas Geraes, Brazil
[19]Inserm U1094, IRD UMR270, Univ. Limoges, CHU Limoges, EpiMaCT - Epidemiology of chronic diseases in tropical zone, Institute of Epidemiology and Tropical Neurology, Omega Health, Limoges, France
[20]Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC, Amsterdam, The Netherlands
[21]Department of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije University, Amsterdam, The Netherlands.
[22]Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA
[23]Division of Psychological Medicine and Clinical Neuroscience, School of Medicine, Cardiff University, Wales, UK
[24]Complex Genetics of Alzheimer's Disease Group, VIB Center for Molecular Neurology, VIB, Antwerp, Belgium
[25]Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium
[26]Boston University and the NHLBI's Framingham Heart Study, Boston, MA, USA
[27]Department of Neurology, Boston University School of Medicine, Boston, MA, USA
[28]Department of Biochemistry and Structural Biology, University of Texas Health Science Center, San Antonio, TX, USA
[29]Department of Population Health Sciences, University of Texas Health Science Center, San Antonio, TX, USA
[30]German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany
[31]Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Institute of Psychiatry and Psychotherapy, Berlin, Germany
[32]German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany
[33]Department for Neurodegenerative Diseases and Geriatric Psychiatry, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany
[34]Institute for Stroke and Dementia Research (ISD), University Hospital, LMU Munich, Munich, Germany.
[35]German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
[36]Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
[37]Department of Psychiatry and Comprehensive Center of Neuroscience and Mental Health, Medical University of Vienna, Vienna, Austria

[38]Department of Psychiatry and Psychotherapy, LVR-Klinikum Essen, University of Duisburg-Essen, Germany Medical Faculty, Germany
[39]Department of Psychiatry, Psychosomatics and Psychotherapy, Center of Mental Health, University Hospital of Würzburg, Germany
[40]Institute of Social Medicine, Occupational Health and Public Health, University of Leipzig, 04103 Leipzig, Germany.
[41]Department of Geriatric Psychiatry, Central Institute for Mental Health Mannheim, Faculty Mannheim, University of Heidelberg, Germany
[42]Neurological Tissue Bank - Biobanc- Hospital Clinic -FRCB - IDIBAPS, Barcelona, Spain
[43]Alzheimer's disease and other cognitive disorders Unit. Neurology Department, Hospital Clinic, Barcelona, Spain
[44]German Center for Neurodegenerative Diseases (DZNE), Magdeburg, Germany
[45]Institute of Cognitive Neurology and Dementia Research (IKND), Otto-von-Guericke University, Magdeburg, Germany
[46]Center for Cognitive Disorders, Department of Psychiatry and Psychotherapy, Technical University of Munich, School of Medicine, Munich, Germany
[47]Department of Psychiatry and Psychotherapy, University Medical Center Goettingen, Goettingen, Germany
[48]German Center for Neurodegenerative Diseases (DZNE), Goettingen, Germany
[49]Medical Science Department, iBiMED, Aveiro, Portugal
[50]Institute of Human Genetics, University of Bonn, School of Medicine & University Hospital Bonn, Bonn, Germany
[51]Institute for Urban Public Health, University Hospital Essen, University Duisburg-Essen, Germany
[52]1st Department of Neurology, Medical school, Aristotle University of Thessaloniki, Thessaloniki, Makedonia, Greece
[53]1st Department of Neurology, Aiginition Hospital, National and Kapodistrian University of Athens, Medical School, Greece
[54]Depatment of Neurology, Columbia University, New York, NY, USA
[55]Genetics of Neurodegenerative Diseases Unit IIB Sant Pau, Barcelona, Spain
[56]Department of Neurology. Hospital Universitario Donostia. San Sebastian, Spain
[57]Neurosciences Area. Instituto Biogipuzkoa. San Sebastian, Spain
[58]Unitat de Genètica Molecular, Institut de Biomedicina de València-CSIC, Valencia, Spain
[59]Centro de Biología Molecular Severo Ochoa (UAM-CSIC), Spain
[60]Instituto de Investigacion Sanitaria 'Hospital la Paz' (IdIPaz), Madrid, Spain
[61]Universidad Autónoma de Madrid
[62]Unit of Neurodegenerative diseases, Department of Neurology, University Hospital Germans Trias i Pujol, Badalona, Barcelona, Spain
[63]The Germans Trias i Pujol Research Institute (IGTP), Badalona, Barcelona, Spain
[64]Alzheimer's disease and other cognitive disorders unit. Service of Neurology. Hospital Clínic of Barcelona. Institut d'Investigacions Biomèdiques August Pi i Sunyer, University of Barcelona, Barcelona, Spain
[65]Laboratorio de Genética. Hospital Universitario Central de Asturias, Oviedo, Spain
[66]Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Spain
[67]Center of Neuropsychiatry and Behavior Neurology, School of Medicine, University of Buenos Aires, Argentina
[68]Hospital Interzonal General de Agudos-Eva Perón, Argentina
[69]Laboratory of Brain Aging and Neurodegeneration. Fundacion Instituto Leloir-IIBBA, Argentina
[70]Studies in Neuroscience and Complex Systems Unit-CONICET-HEC-UNAJ, Argentina
[71]Research Center and Memory clinic. ACE Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Spain
[72]Unidad de Trastornos del Movimiento, Servicio de Neurología y Neurofisiología. Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla, Seville, Spain
[73]Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen de Valme, Spain
[74]Depatamento de Bioquímica Médica, Biología Molecular e Inmunología. Facultad de Medicina. Universidad de Sevilla. Sevilla, Spain
[75]Unitat Trastorns Cognitius, Hospital Universitari Santa Maria de Lleida, Lleida, Spain
[76]Institut de Recerca Biomedica de Lleida (IRBLLeida), Lleida, Spain
[77]Alzheimer Research Center & Memory Clinic, Andalusian Institute for Neuroscience, Málaga, Spain.
[78]Depatamento de Especialidades Quirúrgicas, Bioquímica e Inmunología. Facultad de Medicina. Universidad de Málaga. Málaga, Spain

[79]Neurology Service, Marqués de Valdecilla University Hospital (University of Cantabria and IDIVAL), Santander, Spain.
[80]Institute of Clinical Medicine - Neurology, University of Eastern Finland, Finland
[81]Institute of Biomedicine, University of Eastern Finland, Finland
[82]Faculty of Medicine, University of Lisbon, Portugal
[83]Clinic of Neurology, UH "Alexandrovska", Medical University - Sofia, Sofia, Bulgaria
[84]Department of Neurology, UH "Alexandrovska", Medical University, Sofia, Bulgaria
[85]Memory Clinic, Department of Neurology, Charles University, 2nd Faculty of Medicine and Motol University Hospital, Czech Republic
[86]International Clinical Research Center, St. Anne's University Hospital Brno, Brno, Czech Republic
[87]Department of Clinical Biochemistry, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
[88]Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
[89]Department of Clinical Genetics, VU University Medical Centre, Amsterdam, The Netherlands
[90]Department of Neurology, ErasmusMC, the Netherlands
[91]Maastricht University, Department of Psychiatry & Neuropsychologie, Alzheimer Center Limburg, Maastricht, the Netherlands
[92]Department of Radiology&Nuclear medicine, ErasmusMC, the Netherlands
[93]Unit for Hereditary Dementias, Theme Aging, Karolinska University Hospital-Solna, 171 64 Stockholm Sweden
[94]Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet and Stockholm University, Stockholm, Sweden
[95]Dept.of Public Health and Carins Sciences / Geriatrics, Uppsala University, Sweden
[96]Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), 91057, Evry, France
[97]Department of Surgery, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Geraes, Brazil
[98]Department of Psychiatry, Federal University of Minas Gerais (UFMG) Belo Horizonte, Minas Geraes, Brazil
[99]Psychiatry Service of the University Hospital, Federal University of Minas Gerais, Belo Horizonte, Minas Geraes, Brazil
[100]The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida, USA
[101]Department of Medical and Molecular Genetics, Indiana University, Indianapolis, Indiana, USA
[102]Department of Psychiatry, Washington University School of Medicine, St. Louis, MO 63110, USA
[103]NeuroGenomics and Informatics Center, Washington University School of Medicine, St. Louis, MO 63110, USA
[104]Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, Ohio, USA
[105]Department of Biostatistics, Boston University, Boston, Massachusetts, USA
[106]Department of Epidemiology, Boston University, Boston, Massachusetts, USA
[107]Department of Medicine (Biomedical Genetics), Boston University, Boston, Massachusetts, USA
[108]Department of Neurology, Boston University, Boston, Massachusetts, USA
[109]Department of Ophthalmology, Boston University, Boston, Massachusetts, USA
[110]Department of Biostatistics, Boston University School of Public Health, Boston, MA, USA
[111]Department of Genome Sciences, University of Washington, Seattle, Washington, USA
[112]Department of Medicine (Medical Genetics), University of Washington, Seattle, Washington, USA
[113]Department of Biostatistics, University of Washington, Seattle, Washington, USA
[114]Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, New York, USA
[115]Gertrude H. Sergievsky Center, Columbia University, New York, New York, USA
[116]Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami, Miami, Florida, USA
[117]Department of Neuroscience, Mount Sinai School of Medicine, New York, New York, USA
[118]Penn Neurodegeneration Genomics Center, Department of Pathology and Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
[119]Department of Neurology, Columbia University, New York, New York, USA
[120]Uniformed Services University of the Health Sciences; The American Genome Center, Bethesda, USA
[121]Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNR-MAJ, F 76000 Rouen, France
[122]Inserm, Bordeaux Population Health Research Center, UMR 1219, Univ. Bordeaux, ISPED, CIC 1401-EC, Univ Bordeaux,Bordeaux, France
[123]CHU de Bordeaux, Pole santé publique, Bordeaux, France
[124]Univ Lille Inserm 1171, CHU Clinical and Research Memory Research Centre (CMRR) of Distalz Lille France.
[125]Université de Paris, EA 4468, APHP, Hôpital Broca, Paris, France
[126]University Bordeaux, Inserm, Bordeaux Population Health Research Center, France

[127]Department of Neurology, Bordeaux University Hospital, Bordeaux, France
[128]Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, University of Zurich, Zurich, Switzerland
[129]Neuroscience Center Zurich, University of Zurich and ETH Zurich, Switzerland
[130]Zurich Center for Integrative Human Physiology, University of Zurich, Switzerland
[131]Old Age Psychiatry, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland
[132]Department of Geriatric Psychiatry, University Hospital of Psychiatry Zürich, Zürich, Switzerland
[133]Institute for Regenerative Medicine, University of Zürich, Switzerland
[134]Public Health Nutrition Unit, Institute of Nutrition and Food Technology, University of Chile, Chile
[135]Interuniversity Center for Healthy Aging RED21993, Chile
[136]Biomedica Research Group, Centro de Estudios Clínicos, Santiago, Chile
[137]Departamento de Psiquiatría y Salud Mental, Campus Oriente, Facultad de Medicina, Universidad de Chile, Santiago, Chile
[138]Instituto Nacional de Geriatría, Santiago, Chile
[139]Geroscience Center for Brain Health and Metabolism, Santiago, Chile
[140]Latin American Institute for Brain Health (BrainLat), Universidad Adolfo Ibanez, Chile
[141]Memory and Neuropsychiatric Center (CMYN) Neurology Department, Hospital del Salvador y Facultad de Medicina, Universidad de Chile. Santiago, Chile
[142]Interuniversity Center for Healthy Aging RED21993, santiago, Chile
[143]Geriatrics Section Clinical Hospital University of Chile, Chile
[144]Neurology Service Hospital del Salvador, Santiago, Chile
[145]Centre for Precision Health, Edith Cowan University, Joondalup, Perth, Australia
[146]Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, Perth, Australia
[147]Curtin Health Innovation Research Institute, Curtin University, Bentley, Perth, Australia
[148]Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia
[149]Center of Excellence for Stress and Mental Health (CESAMH), VA San Diego Healthcare System, San Diego, CA, USA
[150]Center for Behavior Genetics of Aging, University of California San Diego, La Jolla, CA, USA
[151]VA San Diego Healthcare System, San Diego, CA, USA; Department of Psychiatry
[152]Department of Psychiatry, University of California San Diego, La Jolla, CA, USA
[153]Center of Excellence for Stress and Mental Health, VA San Diego Healthcare System, San Diego, CA, USA
[154]Center for Behavior Genetics of Aging, University of California, San Diego, La Jolla, CA, USA
[155]5Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System, Boston, MA, USA
[156]Division of Aging, Brigham & Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA
[157]Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy
[158]Neurodegenerative Diseases Unit, Fondazione IRCCS Ca' Granda, Ospedale Policlinico, Milan, Italy
[159]Dept. of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy
[160]Department of Clinical Sciences and Community Health, University of Milan, 20122 Milan, Italy
[161]Institute of Gerontology and Geriatrics,Department of Medicine and Surgery, University of Perugia, Italy
[162]Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
[163]Interdisciplinary Department of Medicine, Geriatric Medicine and Memory Unit, University of Bari "A. Moro, Bari, Italy
[164]Centre for Memory Disturbances, Lab of Clinical Neurochemistry, Section of Neurology, University of Perugia, Italy
[165]Department of Biomedical Sciences, University of Cagliari, Italy.
[166]Neurology, IRCCS San Gerardo dei Tintori, Monza and University of Milano-Bicocca, Italy
[167]Deaprtment of Clinical and Experimental Sciences, University of Brescia Italy
[168]Department of Continuity of Care and Frailty, ASST Spedali Civili Brescia, Brescia, Italy
[169]Department of Neuroscience, Psychology, Drug Research and Child Health University of Florence, Italy
[170]IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy
[171]Past Director Dementia Unit University of Parma , Parma, Italy
[172]Department of Hematology and Stem Cell Transplant, Vito Fazzi Hospital, Lecce, Italy
[173]Department of Neuroscience "Rita Levi Montalcini", University of Torino, Torino, Italy
[174]Department of Neuroscience, Università Cattolica del Sacro Cuore, Rome, Italy.

[175]Neurology Unit, IRCCS Fondazione Policlinico Universitario A. Gemelli, Rome, Italy.
[176]Laboratory of Neuropsychiatry, IRCCS Santa Lucia Foundation, Rome, Italy
[177]Niigata University, Brain Research Institute, Japan
[178]Research Center, National Center for Geriatrics and Gerontology, Japan
[179]UK Dementia Research Institute, Cardiff University, UK
[180]Institute of Neurology, Catholic University of the Sacred Heart, Rome, Itlay
[181]Department of Neurology, Amitié Hospital, Bangui, Central African Republic
[182]Department of Neurology, Brazzaville University Hospital, Brazzaville, Republic of Congo
[183]Department of Radiology, Indiana University, Indianapolis, Indiana, USA
[184]Department of Psychiatry and Psychotherapy, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
[185]Cluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), University of Cologne, Cologne, Germany
[186]Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
[187]Department of Epidemiology, ErasmusMC, Rotterdam, The Netherlands
[188]Nuffield Department of Population Health Oxford University, Oxford, UK
[189]High Institute of Biotechnology, University of Monastir, Monastir, Tunisia.
[190]Laboratory of Genetics, Immunology and Human Pathology, Faculty of Science of Tunis, University of Tunis El Manar, 2092 Tunis, Tunisia.
[191]Alzheimer's Centre Reina Sofia-CIEN Foundation-ISCIII, 28031 Madrid, Spain.
[192]Dept. of Public Health and Caring Sciences / Geriatrics, Uppsala University, Uppsala, Sweden
[193]Krembil Brain Institute, University Health Network, Toronto, Ontario, Canada
[194]Tanz Centre for Research in Neurodegenerative Diseases, Departments of Medicine and Laboratory Medicine & Pathobiology, University of Toronto, Toronto, Ontario, Canada
[195]Bordeaux, INSERM, Bordeaux Population Health Research Center, UMR 1219, Bordeaux, France
[196]Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy
[197]NORMENT Centre, Division of Mental Health and Addiction, Oslo University Hospital, Oslo, Norway
[198]Institute of Clinical Medicine, University of Oslo, Oslo, Norway
[199]Centre for Neuropsychiatric Genetics and Genomics, School of Medicine, Cardiff University, UK
[200]Research Center and Memory clinic Fundació ACE, Institut Català de Neurociències Aplicades, Universitat Internacional de Catalunya, Barcelona, Spain
[201]Department of Neurodegenerative diseases and Geriatric Psychiatry, University Hospital Bonn, Medical Faculty, Bonn, Germany
[202]Department of Psychiatry & Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, San Antonio, TX, USA
[203]National Center for PTSD, Behavioral Sciences Division, VA Boston Healthcare System, Boston MA
[204]Department of Psychiatry, Boston University Chobanian & Avedisian School of Medicine, Boston MA
[205]Biomedical genetics/Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston MA.
[206]Department of Biostatistics, Boston University School of Public Health, Boston, MA.

We built a genetic risk score (GRS) from the most complete landscape of the Alzheimer disease (AD) genetics. We extended its analysis in 16 European countries and observed a consistent association of this GRS with AD risk, age at onset and cerebrospinal fluid (CSF) AD biomarker levels regardless of the *Apolipoprotein E (APOE)* genotype. This GRS was also associated with AD risk (independently of *APOE*) with a decreasing order of magnitude in those with an European-American, North-African, East-Asian, Latin-American, African-American background respectively. No association of the GRS to AD was seen in sub-Saharan African and Indian populations. This GRS captures information specific to AD as its association decreases as the diagnosis broadens. In conclusion, a simple GRS captures shared genetic information specific to AD between multi-ancestry populations. However, more population diversity is needed to better understand the AD genetic complexity across populations.

Over the past 15 years, genome-wide association studies (GWAS) have successfully identifying the genetic component of multifactorial diseases. This has led to the development of several powerful approaches that help decipher pathophysiological processes and propose potential diagnostic/prognostic tools. These tools include GRS, a cumulative effect score summarizing the information distributed across individual susceptibility genome-wide significant variants or polygenic risk scores (PRS, an extension of GRS to loci of small effect, without genome-wide significant associations to potentially capture additional predictive capacity[1].

Due to high estimate of the genetic component of AD, i.e., heritability of 60-80% in twin studies[2], such GRSs/PRSs have logically been of particular interest in this pathology. Many GRS/PRS have therefore been developed to assess their associations with AD and related disease (ADRD) risk or with ADRD-related endophenotypes such as age at onset[3], brain imaging[4-6] or CSF biomarkers[7,8]. In almost of these studies, the GRSs/PRSs were significantly associated with the quantitative or binary traits of interest. However, comparisons between publications, even for the same trait such as AD risk, appear to be difficult due to obvious differences in the populations analyzed, heterogeneity in summary statistics and in the variants included, or different statistical methods used to calculate the PRSs[9]. In addition, most of the GRSs/PRSs approaches have been developed utilizing European ancestry populations, and only a few studies have investigated the relevance of such tools in different ancestries[10,11].

Recently, a GRS built from the most complete and reliable landscape of AD genetics, including 75 AD risk loci (and 83 independent signals excluding *APOE*) generated by the European Alzheimer & Dementia Biobank (EADB) consortium, was tested in a limited number of European ancestry cohorts[12]. This GRS was found to be associated with the risk of developing future AD/dementia in population-based studies, or of progressing from mild cognitive impairment to AD/dementia. In this context, we decided to validate the association of this GRS with AD risk, CSF biomarker levels and age at onset in populations from 16 European countries. We also decided to extend the study of this GRS to include different ancestries from Asia, Africa and Latin America.

The different populations analyzed in this work are described in Supplementary Table 1. Two main GRSs were calculated (see Supplementary Table 1 for the different adjustments used per population and Supplementary Table 2 for the list of SNPs used); (i) a GRS including the genome-wide significant and independent sentinel SNPs at the loci reported by Bellenguez et al. (referred to as GRS^{ALZ}) and (ii) a GRS including these sentinel SNPs and adjusted for the number of APOE-ε2 and APOE-ε4 alleles ($GRS^{ALZadjAPOE}$).

We first analyzed the association of these GRSs with the risk of developing AD in case-control studies from 16 countries representative of the European genetic diversity of the EADB. All the GRS distributions in cases and controls are shown in Supplementary Figures 1-3. All countries were analyzed independently and the Odd Ratios (ORs) indicate the effect of the GRS as the increase in the risk of AD associated with each additional allele of average risk in the GRS. GRS^{ALZ} appeared to be significantly associated with AD in a homogeneous

manner across Europe. The association of GRS^{ALZ} with AD risk was little affected when the impact of ε2/ε3/ε4 *APOE* alleles ($GRS^{ALZadjAPOE}$) was considered (Fig. 1). Of note, $GRS^{ALZadjAPOE}$ was also associated with a younger age at onset (Supplementary Fig. 4).

We then generated a mega-analysis based on the EADB datasets of the 16 European countries in order to assess in the most precise way, the risk of developing AD according to GRS strata, i.e. 0-2%, 2-5%, 10-20%, 20-40%, 60-80%, 80-90%, 90-95%, 95-98% and finally 98-100%. The 40-60% GRS stratum was used as the reference. In this analysis, we also generated a GRS including the sentinel SNPs of the GWAS loci but also the two SNPs defining the ε2/ε3/ε4 *APOE* alleles ($GRS^{ALZinclAPOE}$). Results are shown in Fig 2A and as expected the risk of developing AD in the most extreme strata is particularly high when APOE is included in the GRS. However, association of GRS^{ALZ} was also significant in all the strata analyzed and not impacted when adjusted for the number of *APOE*-ε2 and *APOE*-ε4 alleles ($GRS^{ALZadjAPOE}$). In the two extreme 0-2% and 98-100% strata, both GRS^{ALZ} and $GRS^{ALZadjAPOE}$ were associated with a decrease of more than 2-fold or an increase of more than 3-fold of the AD risk when compared with the 40-60% stratum (see Fig. 2A and Supplementary Table 3).

Since all the analyses suggested an association of GRS^{ALZ} independently of the *APOE* status, we took advantage of our large mega-analysis to fully address how GRS^{ALZ} interacts with the *APOE* genotypes. For this purpose, we stratified in 4 groups the mega-analysis according to the *APOE* genotype by grouping together the ε2ε2/ε2ε3, ε3ε3, ε2ε4/ε3ε4, ε4ε4 carriers. We then assessed in each of these subpopulations, the association of GRS^{ALZ} with AD risk per quintile strata (0-20%, 20-40%, 60-80% and 80-100%) with the 40-60% stratum as a reference. Remarkably, GRS^{ALZ} appeared to be homogenously associated with AD risk in all the strata indicating that the *APOE* and GRS^{ALZ} risk are independent (Fig. 2B and Supplementary Table 4).

To determine whether these GRSs are associated with pathophysiological processes known to be involved in the AD pathology, we used a large GWAS on CSF Aβ42, Tau and p-Tau that we generated through EADB, including 5,944 individuals[13]. GRS^{ALZ} was associated with a decrease in Aβ42 levels and with an increase in Tau and pTau levels that fits with the increased AD risk associated with this GRS (Fig. 3). $GRS^{ALZadjAPOE}$ was similarly significantly associated with these endophenotype levels (Fig. 3). It should be noted that although the association of these GRSs with the level of Aβ42 in CSF appears to be highly heterogeneous between populations, their associations with the levels of Tau and p-Tau are, on the contrary, highly homogeneous in the same populations. This could be interpreted as Tau and p-Tau concentrations directly reflecting pathophysiological processes (probably neuronal) that depend on the genetic factors of Alzheimer's disease. CSF Aβ42 concentrations, on the other hand, would depend on multiple intermediate processes, leading to the heterogeneity observed between the different populations.

Following the assessment of these GRS associations with AD risk and endophenotypes in European populations, we thought to extend their analyses to other European-ancestry populations (USA) but to include also populations from India, East-Asia (China, Japan and Korea), North-Africa (Tunisia), sub-Saharan Africa (Central African Republic/the Congo Republic), South-America (Argentina, Brazil, Chile, and Colombia) as well as African-, Native- and Latino-American admixture populations from US studies (more than 75% African- or Native-American ancestry or self-reporting for Latino-American populations) (Fig. 4). With the exception of Korea, where 71 SNPs were available, most GRSs were constructed from 79-85 SNPs including APOE variants, supplementary Table 2). All the GRS distributions in cases and controls are shown in Supplementary Figure 5-7. Of note, the association of *APOE* with AD risk was heterogonous between these different populations as previously described in several prior studies (Figure 4 and Supplementary Table 5)[14,15].

As expected, the AD risk associated with GRS^{ALZ} or $GRS^{ALZadjAPOE}$ was highly similar between European and other European-ancestry populations (USA). Both GRSs were significantly associated with AD risk with a decreasing order of magnitude from Maghreb, East-Asian countries, Latino-American to African-American population admixture (Fig. 5 and

Supplementary Table 6). However, these GRSs had no association with risk of AD in the sub-Saharan African and Indian populations. This may be related to the small sample size, which resulted in the study lacking statistical power. However, in African-American admixture, the magnitude of association decreased as the African ancestry percentage increases, to finally reach a level similar to that observed in our sub-Saharan African population: association of $GRS^{ALZadjAPOE}$ with AD risk populations with more than 90% African ancestry is OR=1.02 (95% CI 1.00-1.05, $P=9x10^{-2}$). This observation supports the expectation that GRSs constructed on genetic data generated from European ancestry populations perform poorly in African ancestry populations. Similarly, in ADSP Native-American admixture, the magnitude of association decreased as the Native-American ancestry percentage increases (from OR=1.05 95% CI 1.03-1.07, $P=4.1x10^{-6}$, OR=1.04 95% CI 1.02-1.06, $P=9.0x10^{-4}$ to OR=1.03 95% CI 1.01-1.06, $P=5.0x10^{-3}$, respectively in the populations with more than 50%, 75% and 90% Native-American ancestry). Notably, a similar finding was seen in Chilean and Argentinian populations where the GRS^{ALZ} association diminishes when the Native American ancestry rises[16]. Of note, $GRS^{ALZadjAPOE}$ was also associated with a younger age at onset in most of the populations studied (at least 100 AD cases) at the notable exception of the Chinese and Korean populations Supplementary Fig. 8). Of note, the APOE $\varepsilon2/\varepsilon3/\varepsilon/4$ alleles strongly influence age at onset in these two populations (Supplementary Fig. 9).

To refine our analysis in multi-ancestry populations, we calculated the association of $GRS^{ALZadjAPOE}$ and $GRS^{ALZinclAPOE}$ with AD risk per quintile strata (0-20%, 20-40%, 60-80% and 80-100%) with the 40-60% stratum as a reference in all our populations. Of note, Salsa, Indian, North-Africa and sub-Saharan Africa populations were excluded because of their small sample size. Results were then meta-analyzed in order to increase statistical power. Consistent with the results shown in Figure 5, the $GRS^{ALZadjAPOE}$ association is very similar between the European-ancestry and East-Asian populations, but less marked with the Latino-American populations and the African-American admixture populations (Fig. 6 and supplementary Table 7).

Finally, we took advantage of the Million Veteran Project (MVP) to assess how the association of $GRS^{ALZadjAPOE}$ with the risk of AD behaved in multi-ancestry populations according to the diagnosis of dementia, that is, to see how a GRS derived from case/control studies using a specific diagnosis of AD performed when the diagnosis was broadened to dementia. $GRS^{ALZadjAPOE}$ showed a decreasing association with AD risk as the diagnosis became less specific, irrespective of the multi-ancestry populations studied (Table 1).

By studying a large multi-ancestry diversity, our work highlights the importance of cross-ancestry studies in unravelling the genetic complexities of this devastating disease and contributes significantly to the understanding of AD risk assessment in diverse populations. The vast majority of GWAS data available worldwide have been developed in European-ancestry populations and the study of the genetics of AD is no exception, especially as the diagnosis of the disease is most often based on specialized clinical structures. This makes studying this disease more difficult in low- and middle-income countries. This is beginning to change as new case-control studies are developed worldwide. However, it is difficult to compare the results obtained in European-ancestry GWASs since GWAS studies in these non-European populations are currently of a size that is at best comparable to that of European studies in the early 2010s[17,18]. These studies are therefore underpowered to detect at a genome-wide significant level most of the loci found in European populations. In addition, the small size of some of these populations means that there is a risk of generating false positives, as in silico replication is difficult given the sparsity of samples from that population.

To address some of these limitations, we have chosen to develop a simple approach to better compare AD genetics across many populations worldwide. We used a GRS combining sentinel SNPs associated with the risk of developing AD in populations of European origin, as described previously[12]. We tested its association with the risk of developing AD in the largest panel of diverse populations studied to date. We were able to observe a systematic

association of this GRS with all the populations under study, with the exception of Indian and African Sub-Saharan populations, probably partly due to lack of statistical power. Our results thus suggest that all multi-ancestry populations are likely to be affected by shared pathophysiological processes driven in part by these genetic risk factors.

However, this study also reveals important differences between populations, especially in African-ancestry populations: ORs are lowest for populations from African countries or of African-American admixture, with the ORs in African-American population, when their % African ancestry reaches 90%, being similar to those measured in populations from sub-Saharan African countries. Our work thus suggests that the AD genetic architecture in African-ancestry populations strongly differs from European-ancestry populations. Higher genetic diversity is observed in African-ancestry populations compared to non-African-ancestry populations[19-21] and this likely implicates different causal variants in already known loci (as previously described for ABCA7[22] and/or different genes involved in the AD pathophysiology as previously proposed in[23,24]).

Such Genetic diversity likely explains part of the potential methodological reason for these variations of the GRS^{ALZ} association across populations. First, although we attempted to develop a comparable GRS, some SNPs were not present in all the populations studied or were poorly imputed, with the likely consequence of underestimating the association of GRSs with AD risk in these populations. However, as these points mainly affect low-frequency variants (see Supplementary Table 2), their impacts on GRSs are likely to be limited. It should be noted that, limiting this imputation problem, some of the genetic data were generated from whole genome sequencing (Alzheimer disease sequencing project (ADSP) and China). Second, we used sentinel variants defined by populations of European ancestry. Most of these are unlikely to be the causal variants and therefore, they do not capture properly the association of a locus with the risk of developing AD in other ancestries as the linkage disequilibrium structure of the genome changes across ancestries. This has already been described for a number of other diseases and populations. The implementation of a PRS calculated based on well-powered GWAS data generated in the target population might solve this problem[25,26]. However, such an approach will require access to raw GWAS data from different populations to generate accurate multi-ancestry PRSs as for instance already generated in kidney diseases[27]. Finally, it has been estimated that around 10-20% of AD dementia is misdiagnosed, and we have observed that the more inaccurate the clinical diagnosis of AD dementia, the smaller the magnitude of the association in the GRS. This observation suggests that our current GRSs capture information specific to AD, but that the quality of the clinical diagnose may interfere with measuring the association of this GRS with the AD risk in a given population. This last point will have to be better controlled in the future with the introduction of standardized diagnosis between different populations, for example, based on biological markers (although there is also a need for more diversity in this field to define the relevance of biomarkers in multi-ancestry populations).

Finally, our study also confirms the strong heterogeneity in the *APOE* ε2/ε3/ε4 associations with AD risk in different populations (Figure 4). Differential regulation of APOE expression related to different ancestral genomic background around the locus have been proposed to account for the differences in risk between populations of various ancestries[28-31]. In addition, it has also been postulated that interaction with other genetic risk factors for AD may be an explanation for this heterogeneity. However, our data also clearly indicate that GRS^{ALZ} appears to be associated with AD risk regardless of APOE status whatever the population studied. This observation suggests that we may have two independent genetic entities for sporadic AD which fits remarkably well with the recent hypothesis of three variants of AD (autosomal dominant AD, *APOE* ε4-associated sporadic AD and *APOE* ε4-unassociated sporadic AD) that may lead to a possible revision of the current clinical taxonomy of AD[32].

In conclusion, our various observations are a call for more genetic diversity in the study of Alzheimer's disease. Although a simple GRS based on the largest European-ancestry GWAS can capture relevant genetic information in most studied populations worldwide, there appears to be important genetic heterogeneity between these populations. Characterizing the global genetic architecture of AD in multi-ancestry populations (particularly African-

ancestry) may have important implications for understanding the pathophysiology of AD and accelerating the development of strategies to prevent and treat AD.

Acknowledgments

We thank the many study participants, researchers, and staff for collecting and contributing to the data and the high-performance computing service at the University of Lille. This work was funded by a grant (European Alzheimer&Dementia DNA BioBank, EADB) from the EU Joint Programme – Neurodegenerative Disease Research (JPND) and the Fondation Recherche Alzheimer. A.N. was supported by Fondation pour la recherche médicale (EQU202003010147). UMR1167 is also funded by the Inserm, Institut Pasteur de Lille, Lille Métropole Communauté Urbaine, and the French government's LABEX DISTALZ program (development of innovative strategies for a transdisciplinary approach to Alzheimer's disease). Full consortium acknowledgements and funding are in the Supplementary Note.

Author contributions

Project coordination: A.N., J-C.L; **data collection coordination**: A.N., Y.LG., J.G., M.D.G., E.N.D.M., J-F.D., H.A., V.E-P., A.Rui., K.H.L., T.I., A.Ram., M.L., J-C.L; **Data analyses**: A.N, B.G-B., R.S., Y.K., M.K., I.D.R., C.D., X.Z., Y.L.G. C.E.A-B., M.A.C.B., M.Gue., S.v.d.L., M.Gos., A.C., C.B., F.K; **EADB Sample contribution**: I.d.R., A.C., S.V.D.L,., C.B., F.K., O.P., A.Sch., M.D., D.R., N.Sch., D.J., S.R-H., L.H., L.M.P., E.D., O.G., J.Wilt., S.H-H., S.Moe., T.T., N.Sca., J.C., F.M., J.P-T., M.J.B., P.P., R.S-V., V.Á. M.B., P.G-G., R.Pue., P.Mir., L.M.R., G.P-R., J.M.G-A., J.L.R., E.R-R., H.S., T.K., A.d.M., S.Meh., J.Hor., M.V., K.L.R., J.Q.T., Y.A.P., H.H. J.v.S., I.Ram., F.V., A.v.d.L. P.Sch., C.G., G.P., V.G., G.N., C.Duf., F.P., O.H., S.D., A.B., J-F.Del., E.G., J.P., D.G., B.Aro., P.Mec., V.S., L.P., A.Squ., L.T., B.Bor., B.N., P.C., D.S., I.Rai., A.Dan., J.Will., C.Mas., P.A., F.J., P.K., C.V.D., R.F-S., T.M., P.S-J., K.S., M.I., G.R., M.H., R.Sim., W.v.d.F., O.A., A.Rui., A.Ram., J-C.L., **MVP Sample contribution:** R.She., R.H., V.M., M.P., R.Z., M.Gaz., M.L.**; Salsa Sample contribution:** M.Gos., C.S.B., B.F., Q.Y. S.S.; **ADSP Sample contribution:** A.Gri., T.F., C.Cru., J.Hai., L.F., A.Des., E.W., R.M., M.P-V., B.K., A.Goa., G.D.S., B.V., L-S.W., Y.Y.L., C.Dalg., A.Say., S.S.**; Africa sample contribution:** M.Gue., P-M.P., P.Mbe, B.Ban, J-F.Dar.**; East-Asia sample contribution:** Y.K., M.K., X.Z., H.C., N.Y.I., A.K.Y.F., F.C.F.I., A.M., N.H., K.O., S.N., J.G., V.E-P., K.H.L., T.I.**; South America sample contribution:** C.Dalm., C.E.A-B., M.A.C.B., N.O., C.Muc., C.Cue., L.Cam., P.Sol., D.G.P., S.K., L.I.B., J.O-R., A.G.C.M.,M.F.M., R.Par., G.A., L.A.d.M., M.A.R.S., B.d.M.V., M.T.G.C., B.Ang., S.G., M.V.C., R.A., P.O., A.Sla., C.G-B., C.A., P.F., E.N.d.M., L.M., H.A., A.Rui., A.Ram**; Core writing group**: A.N, B.G-B., J-C.L.

Competing Interests Statement

C.C. has received research support from: GSK and EISAI. The funders of the study had no role in the collection, analysis, or interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. CC is a member of the advisory board of Vivid Genomics and Circular Genomics and owns stocks. L.M.P. received personal fees from Biogen for consulting activities unrelated to the submitted work T.G. received consulting fees from AbbVie, Alector, Anavex, Biogen, Cogthera, Eli Lilly, Functional Neuromodulation, Grifols, Iqvia, Janssen, Noselab, Novo Nordisk, NuiCare, Orphanzyme, Roche Diagnostics, Roche Pharma, UCB, and Vivoryon; lecture fees from Biogen, Eisai, Grifols, Medical Tribune, Novo Nordisk, Roche Pharma, Schwabe, and Synlab; and has received grants to his institution from Biogen, Eisai, and Roche Diagnostics.

References

1. Osterman, M.D. et al, Polygenic Risk Scores. *Curr. Protoc*. **1**, e126 (2021)
2. Gatz, M. et al,. Role of genes and environments for explaining Alzheimer disease. *Arch. Gen. Psychiatry* **63**, 168-74 (2006)
3. Desikan, R.S. et al, Genetic assessment of age-associated Alzheimer disease risk: Development and validation of a polygenic hazard score. *PLoS Med*. **14**, e1002258 (2017)
4. Sabuncu, M.R et al, The association between a polygenic Alzheimer score and cortical thickness in clinically normal subjects. *Cereb. Cortex* **22**, 2653-61 (2012)
5. Mormino, E.C. et al, Polygenic risk of Alzheimer disease is associated with early- and late-life processes. *Neurology* **87**, 481-8 (2016)
6. Xicota, L. et al, Association of APOE-Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults. *Neurology* **99**, e462–75 (2022)
7. Sleegers, K. et al, A 22-single nucleotide polymorphism Alzheimer's disease risk score correlates with family history, onset age, and cerebrospinal fluid Aβ42. *Alzheimers Dement*. **11**, 1452-1460 (2015)
8. Hong, S. et al, Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. *Transl. Psychiatry*. **10**, 403 (2020)
9. Clark, K. et al, Polygenic Risk Scores in Alzheimer's Disease Genetics: Methodology, Applications, Inclusion, and Diversity. *J. Alzheimers Dis*. **89**, 1-12 (2022)
10. Sariya, S. et al, Polygenic Risk Score for Alzheimer's Disease in Caribbean Hispanics. *Ann. Neurol*. **90** 366-376 (2021)
11. Jung, S.H. et al, Transferability of Alzheimer Disease Polygenic Risk Score Across Populations and Its Association With Alzheimer Disease-Related Phenotypes. *JAMA Netw. Open*. **5**, e2247162 (2022)
12. Bellenguez, C. et al, New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat. Genet*. **54**, 412-436 (2022)
13. Jansen, I.E. et al, Genome-wide meta-analysis for Alzheimer's disease cerebrospinal fluid biomarkers. *Acta Neuropathol*. 144, 821-842 (2022)
14. Logue, M.W. Et al. Genetics of Alzheimer's Disease in the African American Population. *J. Clin. Med*. **12**, 5189 (2023)
15. Miyashita, A. et al, Genetics of Alzheimer's disease: an East Asian perspective. J *Hum. Genet*. **68**, 115-124 (2023)
16. Dalmasso MC, et al, First GWAS on Alzheimer’s Disease in Argentina and Chile populations. medRxiv, doi.10.1101/2023.01.16.23284609
17. Hollingworth, P; et al, Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. *Nat. Genet*. **43**, 429-435 (2011)
18. Naj, A.C. et al, Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nat. Genet* **43**,436-41 (2011)
19. Campbell, M.C. Et al, African genetic diversity: implications for human demographic history, modern human origins, and complex disease mapping. Annu. Rev. Genomics *Hum. Genet*. **9**, 403-33 (2008)
20. Taliun, D. et al, Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature* **590**, 290-299 (2021)
21. Byrska-Bishop, M. et al, High-coverage whole-genome sequencing of the expanded 1000 Genomes Project cohort including 602 trios. *Cell* **185**, 3426-3440 (2022)
22. Reitz, C. et al, Alzheimer Disease Genetics Consortium. Variants in the ATP-binding cassette transporter (ABCA7), apolipoprotein E ϵ4,and the risk of late-onset Alzheimer disease in African Americans. *JAMA* **309**, 1483-92 (2013)
23. Kunkle, B.W. et al, Novel Alzheimer Disease Risk Loci and Pathways in African American Individuals Using the African Genome Resources Panel: A Meta-analysis. *JAMA Neurol*. **78**, 102-113 (2021)

24. Sherva, R. et al, African ancestry GWAS of dementia in a large military cohort identifies significant risk loci. *Mol. Psychiatry* **28**, 1293-1302 (2023)
25. Choi, SW. et al, Tutorial: a guide to performing polygenic risk score analyses. *Nat. Protoc.* **15**, 2759-2772 (2020)
26. Wand, H. et al, Improving reporting standards for polygenic scores in risk prediction studies. *Nature* **591**, 211-219 (2021)
27. Khan, A. et al, Genome-wide polygenic score to predict chronic kidney disease across ancestries. *Nat. Med*. **28**, 1412-1420 (2022)
28. Rajabli, F. et al, Ancestral origin of ApoE ε4 Alzheimer disease risk in Puerto Rican and African American populations. PLoS Genet. 14, e1007791 (2018)
29. Bussies, P.L., et al, Use of local genetic ancestry to assess TOMM40-523' and risk for Alzheimer disease. *Neurol. Genet*. **6**, e404 (2020)
30. Nuytemans, K. et al, Identifying differential regulatory control of APOE ε4 on African versus European haplotypes as potential therapeutic targets. Alzheimers Dement. 18, 1930-1942 (2022)
31. Rajabli, F. et al, A locus at 19q13.31 significantly reduces the ApoE ε4 risk for Alzheimer's Disease in African Ancestry. *PLoS Genet*. **18**, e1009977 (2022)
32. Frisoni, GB. et al, The probabilistic model of Alzheimer disease: the amyloid hypothesis revised. *Nat. Rev. Neurosci*. **23**, 53-66 (2022)

METHODS Online

GRS computation

GRS^{ALZ} includes the 83 independent signals associated with AD. $GRS^{ALZinclAPOE}$ have two additional SNPs to the list of 83: rs7412, rs429358, encoding APOE ε2 and APOE ε4 and GRS^{APOE} includes only the SNPs rs7412 and rs429358. The formula used to calculate the different GRSs is as follow:

$$\mathrm{GRS}_{\mathrm{sample}} = \sum_{i=1}^{83}(\beta_i * dosage_{i,\ sample}) * \mathrm{Nvariants} \,/\, \sum \beta$$

Where $dosage_i$ is the risk allele dosage or genotype of $variant_i$. β_i is extracted from stage II meta-analysis summary statistics (including the ADGC, CHARGE and FinnGen data), at the exception of APOE variants, where the β_i are extracted from the summary statistics of the last UK Biobank's GWAS (unpublished data). The last multiplication term is the number of variants divided by the sum of βs. Thanks to this term, one unit of this transformed GRS corresponds to one additional risk allele[33].

Sample and variant Quality controls

To have a complete independence of the βs extracted from summary statistics, all samples from ADGC, CHARGE and FinnGen GWASes were filtered out. After meeting the classical GWAS gold standard of sample quality control, each sample was included in the analyses[34]. If a variant dose, covariate, or discordance between imputed and genotyped (if available) APOE status was observed, the sample was discarded. After QC, a demographic description of each study is shown in Supplementary Table 1.

In case of genotyping data, if the variants are genotyped, they should meet the gold standard of GWAS variant QC[34]. All the studies were also imputed with the TOPmed reference panel[35,36], at the exception of the Korean one, which was imputed with the Haplotype Reference Consortium imputation panel[37]. If the variants were imputed, variants with a Rsq bellow 0.3 were excluded. In case of WGS data, only variants passing the WGS QC are kept (see supplementary information for ADSP and China sample)(Supplementary Table 2). The global ancestry of each individual in ADSP and MVP was determined with SNPweights v.2.1[38] (see supplementary information).

European mega-analysis methods

For the mega-analysis of European countries, we merged samples from 5 datasets : EADB-core, GERAD, EADI, Demgene and Bonn. To adjust for population structure, we computed principal components using the following procedure. From the 146,705 variants used in the principal component analysis of EADB-core[39], we extracted from this list, TOPMed imputed variants having an imputation quality ≥0.9 in each dataset, resulting in 91,353 variants. Then, we put any genotype to missing if none of the genotype probabilities was higher than 0.8. Finally, we merged all datasets and removed variants having a proportion of missing genotypes higher than 0.02 leading to 90,471 variants used for the principal component analysis. This analysis was performed by flashPCA2. Analyses were adjusted for the 14 firsts principal components, the genotyping chip and center.

Statistical analyses

The association of AD status with the GRSs was tested with different models, named according to the GRS and covariates included in the logistic regression (see supplementary Table 1 for covariates).

- Model GRS^{ALZ}: AD ~ GRS^{ALZ} + COV

- Model $GRS^{ALZadjAPOE}$: AD ~ GRS^{ALZ} + COV + number of APOE ε2 alleles + number of APOE ε4 alleles
- Model $GRS^{ALZinclAPOE}$: AD ~ $GRS^{ALZinclAPOE}$ + COV
- Model GRS^{APOE}: AD ~ GRS^{APOE} + COV

Quantile or Percentile analyses

Depending on the value of their GRS, the samples were divided into the reference group or one of the test groups. In the mega-analysis, the reference group corresponded to the 40-60% percentile and was tested across each percentile (0-2%, 2-5%, 5-10%, 10-20%, 20-40%, 60-80%, 80-90%, 95-98%, 98-100%). In the *APOE* stratified analysis, the reference group was defined by the 40-60% percentile and was tested across quantile (0-20%, 20-40%, 60-80%, 80-100%). In the multi-ancestry analyses, the reference group was defined by the 40-60% percentile and was also tested across quantile (0-20%, 20-40%, 60-80%, 80-100%). These analyses were performed by population and then meta-analyzed per ancestry, using the inverse variance method, implemented in METAL[40]. To note, Indian, North-Africa and sub-Saharan Africa populations were excluded because of their small sample size.

- Model GRS^{ALZ}: AD ~ $Group_{0/1}(GRS^{ALZ})$ + COV
- Model $GRS^{ALZadjAPOE}$: AD ~ $Group_{0/1}(GRS^{ALZ})$ + COV + number of APOE ε2 alleles + number of APOE ε4 alleles
- Model $GRS^{ALZinclAPOE}$: AD ~ $Group_{0/1}(GRS^{ALZinclAPOE})$ + COV

References

33. Chouraki, V. et al. Evaluation of a genetic risk score to improve risk prediction for Alzheimer's disease. *J. Alzheimers Dis.* **53**, 921–932 (2016).
34. Bellenguez, C. et al, New insights into the genetic etiology of Alzheimer's disease and related dementias. Nat. Genet. 54, 412-436 (2022
35. Taliun, D. et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. *Nature* **590**, 290–299 (2021).
36. Das, S. et al. Next-generation genotype imputation service and methods. *Nat. Genet.* **48**, 1284–1287 (2016).
37. McCarthy, S. et al. A reference panel of 64,976 haplotypes for genotype imputation. *Nat. Genet.* **48**, 1279–1283 (2016).
38. Chen, C.Y. *et al*. Improved ancestry inference using weights from external reference panels. *Bioinformatics* **2,** 1399-406 (2013).
39. Abraham, G. *et al.* FlashPCA2: principal component analysis of Biobank-scale genotype datasets. Bioinformatics **33**, 2776-2778 (2017).
40. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* **26**, 2190–1 (2010).

Data Availability

ADSP: https://dss.niagads.org/datasets/ng00067/

Code availability

Code are available upon requests

Table 1. Association of $GRS^{ALZadjAPOE}$ with AD, AD and related dementia (ADRD) and dementia in MVP.

Ancestry	Disease	Ncases	Ncontrols	$GRS^{ALZadjAPOE}$		
				OR	95% CI	P-value
European American	AD	4,561	84,587	1.10	1.09-1.11	1.73×10^{-88}
	ADRD	17,519		1.06	1.06-1.07	1.94×10^{-111}
	Dementia	26,473		1.05	1.04-1.05	5.82×10^{-83}
US LA Ancestry	AD	375	7,166	1.07	1.04-1.11	1.47×10^{-5}
	ADRD	1,527		1.02	1.00-1.04	1.27×10^{-2}
	Dementia	1,981		1.02	1.00-1.03	2.22×10^{-2}
African American	AD	713	19,405	1.05	1.03-1.08	5.38×10^{-6}
	ADRD	4,016		1.02	1.01-1.02	9.29×10^{-4}
	Dementia	4,702		1.02	1.01-1.03	8.84×10^{-4}

Figure 1: Association of (A) GRS^{alz} and (B) $GRS^{ALZadjAPOE}$ with the risk of developing AD in 15 European countries. Ncase, number of cases; Ncontrols, number of controls; OR, Odds ratio. The lines in the Forrest plots indicate the 95% confidence interval for the ORs.

Figure 2: Relation between the different GRSs and APOE status on the risk of developing AD. (A) Risk of developing AD according to GRS strata (0-2%, 2-5%, 10-20%, 20-40%, 60-80%, 80-90%, 90-95%, 95-98%, 98-100%) for GRS^{ALZ}, $GRS^{ALZadjAPOE}$ and $GRZ^{ALZInclAPOE}$. The 40-60% GRS stratum was used as the reference; **(B)** Risk of developing AD according to GRS^{ALZ} strata (0-20%, 20-40%, 60-80% and 80-100%) and to the *APOE* genotype by grouping together the ε2ε2/ε2ε3, ε3ε3, ε2ε4/ε3ε4, ε4ε4 carriers. The 40-60% GRS stratum was used as the reference.

Figure 3: Association of (A) GRS^{alz} and (B) $GRS^{ALZadjAPOE}$ with the level of Aβ42, Tau and p-TAU in the cerebrospinal fluid in European-ancestry populations. Ncase, number of cases; Ncontrols, number of controls, OR, Odds ratio. The lines in the Forrest plots indicate the 95% confidence interval for the ORs.

Figure 4: World map showing the populations analysed. A colour gradient indicates the magnitude of the association of APOE ε2/ε3/ε4 alleles with the risk of developing AD in different countries (all values are shown in Supplementary Table 5).

Figure 5: Association of (A) GRS^{alz} and (B) $GRS^{ALZadjAPOE}$ with the risk of developing AD in multi-ancestry populations. Ncase, number of cases; Ncontrols, number of controls; OR, Odds ratio. The lines in the Forrest plots indicate the 95% confidence interval for the ORs. African-American-ancestry (more than 75% AA ancestry) meta-analysis includes MVP and ADSP. East-Asia meta-analysis includes China, Korea and Japan. Latino-American ancestry (self-reporting) meta-analysis includes MMVP, ADSP and Salsa. South-America meta-analysis includes Argentina, Brazil, Chile and Colombia.

Figure 6: Risk of developing AD according to GRS (GRS^{ALZ}, $GRS^{ALZadjAPOE}$ and $GRZ^{ALZInclAPOE}$) strata (0-20%, 20-40%, 60-80% and 80-100%) in multi-ancestry populations. Ncase, number of cases; Ncontrols, number of controls; OR, Odds ratio. The lines in the Forrest plots indicate the 95% confidence interval for the ORs. The 40-60% GRS stratum was used as the reference in each population and results were meta-analyzed. African-American ancestry meta-analysis includes MVP and ADSP. East-Asia meta-analysis includes China, Korea and Japan. Latina-American ancestry meta-analysis includes MVP and ADSP. South-America meta-analysis includes Argentina, Brazil, Chile and Colombia.

Figure 1

A

GRS^{ALZ}

$I^2 = 3.9$, HetP = 4.08e-01

Country	Ncases	Ncontrols	OR	95% CI	P-value
Finland	1,118	1,770	1.11	[1.08;1.14]	3.14e-18
Norway	1,327	1,179	1.13	[1.10;1.15]	6.07e-24
Sweden	1,466	3,078	1.14	[1.12;1.16]	1.60e-42
Denmark	398	650	1.13	[1.09;1.18]	5.29e-10
United Kingdom	4,622	8,414	1.13	[1.11;1.14]	8.78e-85
The Netherlands	2,428	2,024	1.11	[1.09;1.13]	3.80e-28
Belgium	1,211	1,431	1.13	[1.10;1.16]	1.58e-18
Germany	2,190	3,141	1.12	[1.10;1.14]	5.71e-43
Switzerland	175	372	1.07	[1.01;1.12]	1.66e-02
Czech Republic	177	60	1.12	[1.02;1.25]	1.97e-02
Bulgaria/Greece	735	1,195	1.10	[1.05;1.14]	1.44e-05
France	3,789	9,026	1.12	[1.11;1.13]	3.19e-85
Italy	2,973	1,251	1.13	[1.10;1.15]	2.52e-31
Spain	3,103	1,615	1.14	[1.12;1.16]	1.48e-41
Portugal	80	74	1.08	[0.98;1.18]	1.14e-01
Meta-analysis	**25,792**	**35,280**	**1.12**	**[1.12;1.13]**	**1.07e-412**



B

$GRS^{ALZadjAPOE}$

$I^2 = 9.2$, HetP = 3.50e-01

Country	Ncases	Ncontrols	OR	95% CI	P-value
Finland	1,118	1,770	1.10	[1.08;1.13]	2.32e-14
Norway	1,327	1,179	1.13	[1.10;1.16]	8.43e-20
Sweden	1,466	3,078	1.14	[1.12;1.17]	2.27e-37
Denmark	398	650	1.13	[1.08;1.17]	2.08e-08
United Kingdom	4,622	8,414	1.12	[1.11;1.14]	3.13e-73
The Netherlands	2,428	2,024	1.10	[1.08;1.13]	6.50e-24
Belgium	1,211	1,431	1.13	[1.10;1.16]	2.20e-17
Germany	2,190	3,141	1.12	[1.10;1.14]	9.18e-37
Switzerland	175	372	1.06	[1.01;1.12]	2.32e-02
Czech Republic	177	60	1.14	[1.03;1.27]	1.81e-02
Bulgaria/Greece	735	1,195	1.10	[1.05;1.15]	1.52e-05
France	3,789	9,026	1.11	[1.10;1.13]	4.69e-73
Italy	2,973	1,251	1.12	[1.10;1.15]	2.15e-27
Spain	3,103	1,615	1.14	[1.11;1.16]	2.91e-36
Portugal	80	74	1.07	[0.98;1.18]	1.42e-01
Meta-analysis	**25,792**	**35,280**	**1.12**	**[1.11;1.13]**	**2.20e-353**



Figure 2

A


30.0
10.0
3.0
1.0
0.3
OR
0-2%
2-5%
5-10%
10-20%
20-40%
60-80%
80-90%
90-95%
95-98%
98-100%
Percentiles
GRS
GRS^ALZ
GRS^ALZajdAPOE
GRS^ALZinclAPOE

B


APOE ε22/ε23
APOE ε33
APOE ε24/ε34
APOE ε44
3.0
2.0
1.0
0.5
OR
0-20%
20-40%
60-80%
80-100%
Percentiles
Percentiles
0-20%
20-40%
60-80%
80-100%

Figure 3

A

$A\beta_{42}$ (GRS^{ALZ})

I^2 = 73.4 , HetP = 4.48e-05

Study	N	Beta	95% CI	P-value
Finland	226	-0.054	[-0.09;-0.01]	8.40e-03
Sweden	264	-0.036	[-0.07;-0.00]	2.88e-02
The Netherlands	3,106	-0.040	[-0.05;-0.03]	4.27e-18
Germany 1	314	-0.029	[-0.06;0.00]	5.66e-02
Germany 2	155	0.013	[-0.04;0.06]	6.05e-01
Germany 3	145	-0.036	[-0.08;0.01]	1.21e-01
Germany 4	112	0.029	[-0.02;0.08]	2.56e-01
Belgium	598	0.008	[-0.01;0.03]	4.46e-01
France 1	439	-0.018	[-0.04;0.01]	1.65e-01
France 2	135	0.019	[-0.02;0.06]	3.68e-01
Spain	408	-0.056	[-0.08;-0.03]	2.10e-05
Meta-analysis	**5,902**	**-0.030**	**[-0.04;-0.02]**	**3.73e-19**
Adjusted for status				**4.05e-07**



B

$A\beta_{42}$ ($GRS^{ALZadjAPOE}$)

I^2 = 66.6 , HetP = 8.80e-04

Study	N	Beta	95% CI	P-value
Finland	226	-0.046	[-0.08;-0.01]	1.22e-02
Sweden	264	-0.017	[-0.05;0.01]	2.52e-01
The Netherlands	3,106	-0.032	[-0.04;-0.02]	1.22e-14
Germany 1	314	-0.012	[-0.04;0.02]	3.99e-01
Germany 2	155	0.006	[-0.04;0.05]	8.21e-01
Germany 3	145	-0.054	[-0.09;-0.01]	1.04e-02
Germany 4	112	0.025	[-0.02;0.07]	3.23e-01
Belgium	598	0.006	[-0.01;0.03]	5.59e-01
France 1	439	-0.008	[-0.03;0.01]	4.87e-01
France 2	135	0.016	[-0.02;0.06]	4.34e-01
Spain	408	-0.040	[-0.06;-0.02]	7.04e-04
Meta-analysis	**5,902**	**-0.024**	**[-0.03;-0.02]**	**1.21e-14**
Adjusted for status				**2.74e-06**



C

Tau (GRS^{ALZ})

I^2 = 0 , HetP = 5.27e-01

Study	N	Beta	95% CI	P-value
Finland	226	0.027	[-0.02;0.08]	3.05e-01
Sweden	264	0.039	[0.01;0.07]	1.17e-02
The Netherlands	3,106	0.036	[0.03;0.04]	1.90e-15
Germany 1	314	0.026	[-0.00;0.06]	7.95e-02
Germany 2	155	0.002	[-0.05;0.05]	9.54e-01
Germany 3	145	0.020	[-0.03;0.07]	3.97e-01
Germany 4	112	-0.026	[-0.07;0.02]	2.82e-01
Belgium	598	0.030	[0.01;0.05]	5.51e-03
France 1	439	0.030	[0.00;0.06]	2.54e-02
France 2	135	0.027	[-0.01;0.07]	2.07e-01
Spain	408	0.041	[0.01;0.07]	2.16e-03
Meta-analysis	**5,902**	**0.032**	**[0.03;0.04]**	**1.29e-21**
Adjusted for status				**6.35e-08**



D

Tau ($GRS^{ALZadjAPOE}$)

I^2 = 0 , HetP = 6.72e-01

Study	N	Beta	95% CI	P-value
Finland	226	0.021	[-0.03;0.07]	4.01e-01
Sweden	264	0.029	[-0.00;0.06]	5.31e-02
The Netherlands	3,106	0.032	[0.02;0.04]	5.43e-13
Germany 1	314	0.015	[-0.01;0.04]	2.90e-01
Germany 2	155	0.001	[-0.05;0.05]	9.66e-01
Germany 3	145	0.026	[-0.02;0.07]	2.71e-01
Germany 4	112	-0.025	[-0.07;0.02]	3.05e-01
Belgium	598	0.029	[0.01;0.05]	5.70e-03
France 1	439	0.023	[-0.00;0.05]	6.72e-02
France 2	135	0.028	[-0.01;0.07]	1.87e-01
Spain	408	0.032	[0.01;0.06]	1.27e-02
Meta-analysis	**5,902**	**0.028**	**[0.02;0.03]**	**2.23e-17**
Adjusted for status				**3.36e-07**



E

pTau (GRS^{ALZ})

I^2 = 0 , HetP = 7.15e-01

Study	N	Beta	95% CI	P-value
Finland	226	0.029	[-0.02;0.08]	2.92e-01
Sweden	264	0.037	[0.01;0.07]	1.89e-02
The Netherlands	3,106	0.032	[0.02;0.04]	3.16e-12
Germany 1	314	0.015	[-0.02;0.04]	3.45e-01
Germany 2	155	-0.008	[-0.06;0.05]	7.82e-01
Germany 3	145	0.009	[-0.04;0.05]	7.08e-01
Germany 4	112	-0.010	[-0.06;0.04]	6.98e-01
Belgium	598	0.022	[0.00;0.04]	3.84e-02
France 1	439	0.028	[0.00;0.05]	3.18e-02
France 2	135	0.012	[-0.03;0.06]	5.94e-01
Spain	408	0.031	[0.00;0.06]	2.27e-02
Meta-analysis	**5,902**	**0.027**	**[0.02;0.03]**	**1.06e-15**
Adjusted for status				**2.00e-05**



F

pTau ($GRS^{ALZadjAPOE}$)

I^2 = 0 , HetP = 8.19e-01

Study	N	Beta	95% CI	P-value
Finland	226	0.025	[-0.03;0.08]	3.56e-01
Sweden	264	0.027	[-0.00;0.06]	8.14e-02
The Netherlands	3,106	0.028	[0.02;0.04]	4.22e-10
Germany 1	314	0.005	[-0.02;0.03]	7.55e-01
Germany 2	155	-0.007	[-0.06;0.05]	7.94e-01
Germany 3	145	0.013	[-0.03;0.06]	5.64e-01
Germany 4	112	-0.012	[-0.06;0.04]	6.44e-01
Belgium	598	0.022	[0.00;0.04]	3.54e-02
France 1	439	0.022	[-0.00;0.05]	7.84e-02
France 2	135	0.014	[-0.03;0.06]	5.38e-01
Spain	408	0.023	[-0.00;0.05]	8.77e-02
Meta-analysis	**5,902**	**0.024**	**[0.02;0.03]**	**2.83e-12**
Adjusted for status				**6.99e-05**



Figure 4



Figure 5

A

GRS^{ALZ}

Country	Ncases	Ncontrols	OR	95% CI	P-value
European American MVP	4,561	84,587	1.10	[1.09;1.11]	2.40e-81
Maghreb	58	187	1.11	[1.00;1.24]	4.81e-02
Sub-Saharan Africa	87	1,113	1.02	[0.98;1.07]	3.07e-01
African American MVP	713	19,405	1.05	[1.02;1.07]	5.12e-05
African American ADSP	1,152	2,451	1.04	[1.02;1.06]	3.75e-05
Meta-analysis AA Ancestry	**1,865**	**21,856**	**1.04**	**[1.03;1.06]**	**8.60e-09**
US LA Ancestry MVP	375	7,166	1.07	[1.04;1.11]	3.38e-05
US LA Ancestry SALSA	79	657	1.03	[0.97;1.10]	3.36e-01
US LA Ancestry ADSP	1,780	2,489	1.06	[1.04;1.07]	6.26e-12
Colombia	254	241	1.07	[1.01;1.12]	1.45e-02
Brazil	301	176	1.11	[1.06;1.16]	1.39e-05
Argentina	417	601	1.08	[1.04;1.12]	1.51e-04
Chile	122	252	1.16	[1.09;1.24]	5.60e-06
Meta-analysis US LA Ancestry	**2,234**	**10,312**	**1.06**	**[1.04;1.07]**	**1.04e-15**
Meta-analysis South America	**1,094**	**1,270**	**1.09**	**[1.07;1.12]**	**1.47e-13**
Meta-analysis LA Ancestry	**3,328**	**11,582**	**1.07**	**[1.05;1.08]**	**1.43e-26**
China	453	786	1.10	[1.05;1.14]	2.33e-06
Japan	1,756	1,865	1.09	[1.06;1.11]	2.08e-14
South Korea	1,119	1,172	1.07	[1.05;1.09]	3.25e-12
Meta-analysis East Asia	**3,328**	**3,823**	**1.08**	**[1.07;1.10]**	**1.05e-29**
India	110	1,548	1.00	[0.95;1.05]	9.37e-01



B

$GRS^{ALZadjAPOE}$

Country	Ncases	Ncontrols	OR	95% CI	P-value
European American MVP	4,561	84,587	1.10	[1.09;1.11]	1.73e-88
Maghreb	58	187	1.10	[0.99;1.23]	9.15e-02
Sub-Saharan Africa	87	1,113	1.02	[0.98;1.07]	3.38e-01
African American MVP	713	19,405	1.05	[1.03;1.08]	5.38e-06
African American ADSP	1,152	2,451	1.03	[1.01;1.05]	4.25e-04
Meta-analysis AA Ancestry	**1,865**	**21,856**	**1.04**	**[1.03;1.06]**	**1.86e-08**
US LA Ancestry MVP	375	7,166	1.07	[1.04;1.11]	1.47e-05
US LA Ancestry SALSA	79	657	1.03	[0.97;1.10]	3.62e-01
US LA Ancestry ADSP	1,780	2,489	1.06	[1.04;1.08]	5.14e-12
Colombia	254	241	1.06	[1.00;1.11]	4.31e-02
Brazil	301	176	1.11	[1.06;1.17]	7.09e-06
Argentina	417	601	1.08	[1.03;1.12]	2.54e-04
Chile	122	252	1.15	[1.08;1.23]	5.96e-05
Meta-analysis US LA Ancestry	**2,234**	**10,312**	**1.06**	**[1.05;1.08]**	**4.75e-16**
Meta-analysis South America	**1,094**	**1,270**	**1.09**	**[1.06;1.12]**	**2.87e-12**
Meta-analysis LA Ancestry	**3,328**	**11,582**	**1.07**	**[1.06;1.08]**	**5.84e-26**
China	453	786	1.09	[1.05;1.14]	1.12e-05
Japan	1,756	1,865	1.09	[1.06;1.11]	9.80e-13
South Korea	1,119	1,172	1.07	[1.05;1.09]	1.47e-10
Meta-analysis East Asia	**3,328**	**3,823**	**1.08**	**[1.06;1.10]**	**1.01e-25**
India	110	1,548	1.00	[0.95;1.05]	9.02e-01



Figure 6

A


GRS^ALZadjAPOE
EUR Ancestry
East Asia
LA Ancestry
AA Ancestry
OR
1.5
1.0
0.7
0.5
0-20%
20-40%
60-80%
80-100%
Percentiles
Ancestry
EUR Ancestry
East Asia
LA Ancestry
AA Ancestry

B


GRS^ALZinclAPOE
EUR Ancestry
East Asia
LA Ancestry
AA Ancestry
OR
5.0
3.0
1.0
0.5
0-20%
20-40%
60-80%
80-100%
Percentiles
Ancestry
EUR Ancestry
East Asia
LA Ancestry
AA Ancestry